Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 3Thoracic 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Neoplasms 1Melanoma 1Liver Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 59Nivolumab 19atezolizumab 8Ipilimumab 8Docetaxel 7avelumab 6Paclitaxel 6cemiplimab 5Specimen Handling 5Cyclophosphamide 5Biopsy 5Taxes 4Pemetrexed 4Magnetic Resonance Spectroscopy 4Interleukin-2 4Gemcitabine 4Carboplatin 4utomilumab 3epacadostat 3durvalumab 3Radiotherapy 3Cisplatin 3Cetuximab 3tremelimumab 2tislelizumab 2sargramostim 2poly ICLC 2obinutuzumab 2fludarabine 2enzalutamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Squamous Cell Carcinoma of Head and Neck × C188-9 compound × Dermatologic × Clear all
NCT03195699 2025-03-21

Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers

Tvardi Therapeutics, Incorporated

Phase 1 Completed
64 enrolled
BreastDermatologicGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Liver Neoplasms, Melanoma, Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡